$CPIX
CUMBERLAND PHARMACEUTICALS INC Stock $cpix

$cpix Overview Financials Valuation SEC Filings Company Website

2016 Q4 Form 10-Q Financial Statement

#000162828016020795 Filed on November 03, 2016

Income Statement

Concept	2016 Q4	2016 Q3	2015 Q4
Revenue	$9.081M	$8.792M	$8.037M
YoY Change	12.99%	11.5%	-13.85%
Cost Of Revenue	$1.610M	$1.974M	$1.590M
YoY Change	1.26%	101.39%	16.91%
Gross Profit	$7.480M	$6.818M	$6.450M
YoY Change	15.97%	-1.26%	-19.07%
Gross Profit Margin	82.37%	77.55%	80.25%
Selling, General & Admin	$6.710M	$5.480M	$5.370M
YoY Change	24.95%	1.43%	-6.45%
% of Gross Profit	89.71%	80.38%	83.26%
Research & Development	$1.160M	$644.7K	$400.0K
YoY Change	190.0%	-14.89%	-48.05%
% of Gross Profit	15.51%	9.46%	6.2%
Depreciation & Amortization	$610.0K	$620.0K	$570.0K
YoY Change	7.02%	14.81%	-6.56%
% of Gross Profit	8.16%	9.09%	8.84%
Operating Expenses	$8.430M	$6.125M	$6.280M
YoY Change	34.24%	-0.58%	-10.54%
Operating Profit	-$957.4K	$130.1K	$162.7K
YoY Change	-688.5%	-51.96%	-82.81%
Interest Expense	$20.00K	$29.09K	$10.00K
YoY Change	100.0%	46.8%	-66.67%
% of Operating Profit		22.35%	6.15%
Other Income/Expense, Net
YoY Change
Pretax Income	-$940.0K	$152.7K	$170.0K
YoY Change	-652.94%	-51.55%	-82.65%
Income Tax	-$170.0K	$57.19K	$40.00K
% Of Pretax Income		37.46%	23.53%
Net Earnings	-$749.7K	$106.2K	$151.1K
YoY Change	-596.29%	-16.15%	-77.42%
Net Earnings / Revenue	-8.26%	1.21%	1.88%
Basic Earnings Per Share	-$0.05	$0.01	$0.01
Diluted Earnings Per Share	-$0.05	$0.01	$0.01
COMMON SHARES
Basic Shares Outstanding	16.18M shares	16.22M shares	16.45M shares
Diluted Shares Outstanding		16.50M shares

Balance Sheet

Concept	2016 Q4	2016 Q3	2015 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$50.13M	$50.15M	$52.77M
YoY Change	-4.99%	-4.94%	-3.55%
Cash & Equivalents	$34.51M	$35.55M	$38.20M
Short-Term Investments	$15.62M	$14.60M	$14.56M
Other Short-Term Assets	$2.711M	$5.161M	$3.998M
YoY Change	-32.19%	3.99%	-20.09%
Inventory	$5.372M	$4.983M	$4.270M
Prepaid Expenses
Receivables	$7.330M	$6.672M	$6.077M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$65.55M	$66.96M	$64.58M
YoY Change	1.49%	-1.12%	-8.8%
LONG-TERM ASSETS
Property, Plant & Equipment	$464.5K	$482.6K	$536.5K
YoY Change	-13.42%	-10.92%	-17.6%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$2.121M	$2.456M	$1.891M
YoY Change	12.15%	-4.53%	5.53%
Total Long-Term Assets	$27.86M	$24.11M	$27.34M
YoY Change	1.92%	-0.93%	11.16%
TOTAL ASSETS
Total Short-Term Assets	$65.55M	$66.96M	$64.58M
Total Long-Term Assets	$27.86M	$24.11M	$27.34M
Total Assets	$93.40M	$91.07M	$91.92M
YoY Change	1.62%	-1.07%	-3.65%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$8.037M	$6.658M	$2.877M
YoY Change	179.29%	61.34%	-11.26%
Accrued Expenses	$6.756M		$9.534M
YoY Change	-29.14%		-9.26%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$14.79M	$11.69M	$12.41M
YoY Change	19.18%	-1.59%	-9.73%
LONG-TERM LIABILITIES
Long-Term Debt	$4.100M	$3.700M	$1.700M
YoY Change	141.18%	117.65%
Other Long-Term Liabilities	$1.391M	$1.300M	$987.4K
YoY Change	40.92%	44.44%	9.37%
Total Long-Term Liabilities	$1.391M	$5.000M	$987.4K
YoY Change	40.92%	92.31%	9.37%
TOTAL LIABILITIES
Total Short-Term Liabilities	$14.79M	$11.69M	$12.41M
Total Long-Term Liabilities	$1.391M	$5.000M	$987.4K
Total Liabilities	$20.28M	$16.65M	$15.10M
YoY Change	34.34%	14.72%	3.05%
SHAREHOLDERS EQUITY
Retained Earnings	$18.60M	$19.35M	$19.55M
YoY Change	-4.83%	-0.23%	3.89%
Common Stock	$54.64M	$55.18M	$57.34M
YoY Change	-4.7%	-5.18%	-7.43%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$73.25M	$74.53M	$76.89M
YoY Change
Total Liabilities & Shareholders Equity	$93.40M	$91.07M	$91.92M
YoY Change	1.62%	-1.07%	-3.65%

Cashflow Statement

Concept	2016 Q4	2016 Q3	2015 Q4
OPERATING ACTIVITIES
Net Income	-$749.7K	$106.2K	$151.1K
YoY Change	-596.29%	-16.15%	-77.42%
Depreciation, Depletion And Amortization	$610.0K	$620.0K	$570.0K
YoY Change	7.02%	14.81%	-6.56%
Cash From Operating Activities	$820.0K	$290.0K	$1.330M
YoY Change	-38.35%	-39.58%	-51.28%
INVESTING ACTIVITIES
Capital Expenditures	-$480.0K	-$500.0K	-$210.0K
YoY Change	128.57%	-261.29%	-85.91%
Acquisitions
YoY Change
Other Investing Activities	-$1.010M	-$20.00K	-$130.0K
YoY Change	676.92%	-92.59%	550.0%
Cash From Investing Activities	-$1.500M	-$520.0K	-$330.0K
YoY Change	354.55%	-1400.0%	-78.15%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-360.0K	-70.00K	-1.090M
YoY Change	-66.97%	-93.97%	9.0%
NET CHANGE
Cash From Operating Activities	820.0K	290.0K	1.330M
Cash From Investing Activities	-1.500M	-520.0K	-330.0K
Cash From Financing Activities	-360.0K	-70.00K	-1.090M
Net Change In Cash	-1.040M	-300.0K	-90.00K
YoY Change	1055.56%	-53.12%	-140.91%
FREE CASH FLOW
Cash From Operating Activities	$820.0K	$290.0K	$1.330M
Capital Expenditures	-$480.0K	-$500.0K	-$210.0K
Free Cash Flow	$1.300M	$790.0K	$1.540M
YoY Change	-15.58%	364.71%	-63.51%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	cpix	Increase Decrease In Current Operating Liabilities IncreaseDecreaseInCurrentOperatingLiabilities	1457656	USD
	cpix	Increase Decrease In Current Operating Liabilities IncreaseDecreaseInCurrentOperatingLiabilities	-1705007	USD
CY2014Q1	cpix	Inventory Extended Shelf Life InventoryExtendedShelfLife	P6Y
CY2015Q1	cpix	Inventory Extended Shelf Life InventoryExtendedShelfLife	P7Y
CY2014Q1	cpix	Inventory Shelf Life InventoryShelfLife	P5Y
CY2015Q1	cpix	Inventory Shelf Life InventoryShelfLife	P6Y
	cpix	Noncashor Part Noncash Acquisition Net Changein Unpaid Additions Fixed Assets NoncashorPartNoncashAcquisitionNetChangeinUnpaidAdditionsFixedAssets	1266759	USD
	cpix	Noncashor Part Noncash Acquisition Net Changein Unpaid Additions Fixed Assets NoncashorPartNoncashAcquisitionNetChangeinUnpaidAdditionsFixedAssets	-82487	USD
CY2015Q4	cpix	Other Long Term Obligations Excluding Current Portion OtherLongTermObligationsExcludingCurrentPortion	987429	USD
CY2016Q3	cpix	Other Long Term Obligations Excluding Current Portion OtherLongTermObligationsExcludingCurrentPortion	1265725	USD
	cpix	Paymentsfor Contingent Consideration PaymentsforContingentConsideration	1618983	USD
	cpix	Paymentsfor Contingent Consideration PaymentsforContingentConsideration	0	USD
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2016
	dei	Document Period End Date DocumentPeriodEndDate	2016-09-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001087294
CY2016Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	16180604	shares
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	CUMBERLAND PHARMACEUTICALS INC
CY2015Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2877479	USD
CY2016Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	6658196	USD
CY2015Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	6077120	USD
CY2016Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	6672300	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	33001	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	61224	USD
CY2015Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	473439	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1471879	USD
CY2016Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	562722	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1632920	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	54798	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	21950	shares
CY2015Q4	us-gaap	Assets Assets	91918959	USD
CY2016Q3	us-gaap	Assets Assets	91074271	USD
CY2015Q4	us-gaap	Assets Current AssetsCurrent	67112074	USD
CY2016Q3	us-gaap	Assets Current AssetsCurrent	66962992	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	39866037	USD
CY2015Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	38316291	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	38203059	USD
CY2016Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	35546244	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-1549746	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-2656815	USD
CY2015Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q4	us-gaap	Common Stock No Par Value CommonStockNoParValue	0
CY2016Q3	us-gaap	Common Stock No Par Value CommonStockNoParValue	0
CY2015Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2016Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2015Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	16379501	shares
CY2016Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	16195631	shares
CY2015Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	16379501	shares
CY2016Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	16195631	shares
CY2015Q4	us-gaap	Common Stock Value CommonStockValue	57338294	USD
CY2016Q3	us-gaap	Common Stock Value CommonStockValue	55175133	USD
CY2015Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	121702	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	542512	USD
CY2016Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	95488	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-234007	USD
CY2015Q3	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	4911	USD
	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	37780	USD
CY2016Q3	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	10678	USD
	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	39018	USD
CY2015Q3	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	126613	USD
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	580292	USD
CY2016Q3	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	106166	USD
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-194989	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1677906	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1785057	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	4353148	USD
CY2015Q3	us-gaap	Costs And Expenses CostsAndExpenses	7614164	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	43991	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	662689	USD
CY2015Q3	us-gaap	Cost Of Goods Sold CostOfGoodsSold	980176	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	3379018	USD
CY2016Q3	us-gaap	Cost Of Goods Sold CostOfGoodsSold	1973948	USD
	us-gaap	Costs And Expenses CostsAndExpenses	24532632	USD
CY2016Q3	us-gaap	Costs And Expenses CostsAndExpenses	8661621	USD
	us-gaap	Costs And Expenses CostsAndExpenses	24419880	USD
CY2015Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.01
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.03
CY2016Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.01
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
CY2015Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.01
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.03
CY2016Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.01
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	470584	USD
	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	-907270	USD
	us-gaap	Excess Tax Benefit From Share Based Compensation Operating Activities ExcessTaxBenefitFromShareBasedCompensationOperatingActivities	470584	USD
	us-gaap	Excess Tax Benefit From Share Based Compensation Operating Activities ExcessTaxBenefitFromShareBasedCompensationOperatingActivities	-907270	USD
CY2015Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	21168596	USD
CY2016Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	21172570	USD
CY2015Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1794279	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5591982	USD
CY2016Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1865575	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5817943	USD
CY2015Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	315141	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	1073397	USD
CY2016Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	152680	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-393289	USD
CY2015Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	193439	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	530885	USD
CY2016Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	57192	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-159282	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	293665	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	595180	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-1394280	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	713084	USD
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	61553	USD
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	267730	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	239484	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	1241372	USD
CY2015Q3	us-gaap	Interest Expense InterestExpense	19815	USD
	us-gaap	Interest Expense InterestExpense	53854	USD
CY2016Q3	us-gaap	Interest Expense InterestExpense	29088	USD
	us-gaap	Interest Expense InterestExpense	77777	USD
CY2015Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1457886	USD
CY2016Q3	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	2027986	USD
CY2015Q4	us-gaap	Inventory Net InventoryNet	4270143	USD
CY2016Q3	us-gaap	Inventory Net InventoryNet	4983227	USD
CY2015Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	2576621	USD
CY2016Q3	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	2618737	USD
CY2015Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	2700000	USD
CY2016Q3	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	700000	USD
CY2015Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	64072	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	178320	USD
CY2016Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	51636	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	160248	USD
CY2015Q4	us-gaap	Liabilities Liabilities	15099176	USD
CY2016Q3	us-gaap	Liabilities Liabilities	16651656	USD
CY2015Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	91918959	USD
CY2016Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	91074271	USD
CY2015Q4	us-gaap	Liabilities Current LiabilitiesCurrent	12411747	USD
CY2016Q3	us-gaap	Liabilities Current LiabilitiesCurrent	11685931	USD
CY2015Q3	us-gaap	Long Term Line Of Credit LongTermLineOfCredit	1700000	USD
CY2015Q4	us-gaap	Long Term Line Of Credit LongTermLineOfCredit	1700000	USD
CY2016Q3	us-gaap	Long Term Line Of Credit LongTermLineOfCredit	3700000	USD
CY2015Q4	us-gaap	Marketable Securities MarketableSecurities	14564115	USD
CY2016Q3	us-gaap	Marketable Securities MarketableSecurities	14600404	USD
CY2015Q4	us-gaap	Minority Interest MinorityInterest	-68125	USD
CY2016Q3	us-gaap	Minority Interest MinorityInterest	-107143	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-4096906	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-786665	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2006336	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1619834	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	4553496	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-250316	USD
CY2015Q3	us-gaap	Net Income Loss NetIncomeLoss	126613	USD
	us-gaap	Net Income Loss NetIncomeLoss	580292	USD
CY2016Q3	us-gaap	Net Income Loss NetIncomeLoss	106166	USD
	us-gaap	Net Income Loss NetIncomeLoss	-194989	USD
CY2015Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-4911	USD
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-37780	USD
CY2016Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-10678	USD
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-39018	USD
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	Segment
CY2015Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	270884	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	948931	USD
CY2016Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	130132	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-475760	USD
CY2015Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3101839	USD
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	3676745	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	21366	USD
CY2015Q4	us-gaap	Other Assets Current OtherAssetsCurrent	3997637	USD
CY2016Q3	us-gaap	Other Assets Current OtherAssetsCurrent	5160817	USD
CY2016Q3	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	44000000	USD
CY2016Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2456118	USD
CY2015Q4	us-gaap	Other Inventory Materials Supplies And Merchandise Under Consignment OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment	235636	USD
CY2016Q3	us-gaap	Other Inventory Materials Supplies And Merchandise Under Consignment OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment	336504	USD
	us-gaap	Proceeds From Repayments Of Lines Of Credit ProceedsFromRepaymentsOfLinesOfCredit	2000000	USD
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	5684149	USD
CY2015Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	9534268	USD
CY2016Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	5027735	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	4669873	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	1879395	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	2392477	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	1554410	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	5201240	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	3643894	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	96768	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	98275	USD
	us-gaap	Proceeds From Repayments Of Lines Of Credit ProceedsFromRepaymentsOfLinesOfCredit	1700000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
CY2015Q3	us-gaap	Profit Loss ProfitLoss	121702	USD
	us-gaap	Profit Loss ProfitLoss	542512	USD
CY2016Q3	us-gaap	Profit Loss ProfitLoss	95488	USD
	us-gaap	Profit Loss ProfitLoss	-234007	USD
CY2015Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	536450	USD
CY2016Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	482591	USD
CY2015Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	757442	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3444524	USD
CY2016Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	644662	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2029914	USD
CY2015Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	19549614	USD
CY2016Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	19354625	USD
	us-gaap	Revenue Recognition Milestone Method Revenue Recognized RevenueRecognitionMilestoneMethodRevenueRecognized	200000	USD
CY2015Q3	us-gaap	Sales Revenue Net SalesRevenueNet	7885048	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	25481563	USD
CY2016Q3	us-gaap	Sales Revenue Net SalesRevenueNet	8791753	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	23944120	USD
CY2015Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	3608828	USD
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	10645229	USD
CY2016Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	3614714	USD
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	10585955	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	426651	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	623504	USD
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	623504	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	-907270	USD
CY2010Q2	us-gaap	Stock Repurchase Program Authorized Amount1 StockRepurchaseProgramAuthorizedAmount1	10000000.0	USD
CY2011Q1	us-gaap	Stock Repurchase Program Authorized Amount1 StockRepurchaseProgramAuthorizedAmount1	10000000.0	USD
CY2012Q2	us-gaap	Stock Repurchase Program Authorized Amount1 StockRepurchaseProgramAuthorizedAmount1	10000000.0	USD
CY2013Q1	us-gaap	Stock Repurchase Program Authorized Amount1 StockRepurchaseProgramAuthorizedAmount1	10000000.0	USD
CY2015Q1	us-gaap	Stock Repurchase Program Authorized Amount1 StockRepurchaseProgramAuthorizedAmount1	10000000.0	USD
CY2016Q1	us-gaap	Stock Repurchase Program Authorized Amount1 StockRepurchaseProgramAuthorizedAmount1	10000000.0	USD
	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	1879395	USD
CY2015Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	76819783	USD
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	76887908	USD
CY2016Q3	us-gaap	Stockholders Equity StockholdersEquity	74529758	USD
CY2016Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	74422615	USD
CY2015Q4	us-gaap	Trading Securities TradingSecurities	14564115	USD
CY2016Q3	us-gaap	Trading Securities TradingSecurities	14600404	USD
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	80321	USD
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	69140	USD
CY2015Q3	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	391694	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	382494	shares
CY2016Q3	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	287126	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
CY2015Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	16996376	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	17193854	shares
CY2016Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	16504568	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	16268579	shares
CY2015Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	16604682	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	16811360	shares
CY2016Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	16217442	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	16268579	shares
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In preparing the condensed consolidated financial statements in conformity with U.S. GAAP, management must make decisions that impact the reported amounts and the related disclosures. Such decisions include the selection of the appropriate accounting principles to be applied and the assumptions on which to base accounting estimates. In reaching such decisions, management applies judgments based on its understanding and analysis of the relevant circumstances, historical experience, and other available information. Actual results could differ from those estimates under different assumptions and conditions. The Company's most significant estimates include: (1) its allowances for chargebacks and accruals for rebates and product returns, (2) the allowances for obsolescent or unmarketable inventory and (3) the projection of future taxable income for the realization of deferred tax assets.</font></div></div>

Files In Submission

Name	View Source	Status
0001628280-16-020795-index-headers.html	Edgar Link	pending
0001628280-16-020795-index.html	Edgar Link	pending
0001628280-16-020795.txt	Edgar Link	pending
0001628280-16-020795-xbrl.zip	Edgar Link	pending
cpix-20160930.xml	Edgar Link	completed
cpix-20160930.xsd	Edgar Link	pending
cpix-20160930_cal.xml	Edgar Link	unprocessable
cpix-20160930_def.xml	Edgar Link	unprocessable
cpix-20160930_lab.xml	Edgar Link	unprocessable
cpix-20160930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
q32016-exhibit311.htm	Edgar Link	pending
q32016-exhibit312.htm	Edgar Link	pending
q32016-exhibit321.htm	Edgar Link	pending
q3201610q.htm	Edgar Link	pending
q32016ex1033amendmenttodeb.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CPIX
CUMBERLAND PHARMACEUTICALS INC Stock $cpix

2016 Q4 Form 10-Q Financial Statement

#000162828016020795 Filed on November 03, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CPIX CUMBERLAND PHARMACEUTICALS INC Stock $cpix

2016 Q4 Form 10-Q Financial Statement

#000162828016020795 Filed on November 03, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CPIX
CUMBERLAND PHARMACEUTICALS INC Stock $cpix